Eliciting broadly protective antibody responses against influenza

Current Opinion in Immunology

Volumn 28, Issue 1, 2014, Pages 71-76

  Kirchenbaum, Greg A ^a   Ross, Ted M ^a  

^a Vaccine and Gene Therapy Institute of Florida   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; NEUTRALIZING ANTIBODY;

ANTIBODY RESPONSE; ANTIGEN ANTIBODY REACTION; ANTIGENICITY; CROSS REACTION; DRUG STRUCTURE; HEMAGGLUTINATION; HUMORAL IMMUNITY; INFLUENZA; INFLUENZA VACCINATION; NONHUMAN; PANDEMIC INFLUENZA; REVIEW; VIRUS STRAIN;

ANIMALS; ANTIBODIES, VIRAL; ANTIBODY FORMATION; ANTIGENS, VIRAL; HEMAGGLUTININS; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN;

EID: 84896019901     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2014.02.005     Document Type: Review

References (59)

1. Palese P.S.M. Orthomyxoviridai: the viruses and their replication. Fields Virology 2006, vol. 2:1647-1689. Lippincott Williams & Watkins. edn 5th.
2. Tong S., Li Y., Rivailler P., Conrardy C., Castillo D.A., Chen L.M., Recuenco S., Ellison J.A., Davis C.T., York I.A., et al. A distinct lineage of influenza A virus from bats. Proc Natl Acad Sci U S A 2012, 109:4269-4274.
3. http://www.cdc.gov/flu/index.htm.
4. Wei S.-H., Yang J.-R., Wu H.-S., Chang M.-C., Lin J.-S., Lin C.-Y., Liu Y.-L., Lo Y.-C., Yang C.-H., Chuang J.-H., et al. Human infection with avian influenza A H6N1 virus: an epidemiological analysis. Lancet Respir Med 2013, 1:771-778.
5. http://www.cdc.gov/flu/protect/keyfacts.htm.
6. Sandbulte M.R., Westgeest K.B., Gao J., Xu X., Klimov A.I., Russell C.A., Burke D.F., Smith D.J., Fouchier R.A., Eichelberger M.C. Discordant antigenic drift of neuraminidase and hemagglutinin in H1N1 and H3N2 influenza viruses. Proc Natl Acad Sci U S A 2011, 108:20748-20753.
7. Yen H.L., Webster R.G. Pandemic influenza as a current threat. Curr Top Microbiol Immunol 2009, 333:3-24.
8. Rogers G.N., Paulson J.C., Daniels R.S., Skehel J.J., Wilson I.A., Wiley D.C. Single amino acid substitutions in influenza haemagglutinin change receptor binding specificity. Nature 1983, 304:76-78.
9. Hobson D., Curry R.L., Beare A.S., Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond) 1972, 70:767-777.
10. Sui J., Hwang W., Perez S., Wei G., Aird D., Chen L.-m., Santelli E., Stec B., Cadwell G., Ali M., et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 2009, 16:265-273.
11. Ekiert D., Bhabha G., Elsliger M.-A., Friesen R., Jongeneelen M., Throsby M., Goudsmit J., Wilson I. Antibody recognition of a highly conserved influenza virus epitope. Science (New York, N.Y.) 2009, 324:246-251.
12. Dreyfus C., Laursen N., Kwaks T., Zuijdgeest D., Khayat R., Ekiert D., Lee J., Metlagel Z., Bujny M., Jongeneelen M., et al. Highly conserved protective epitopes on influenza B viruses. Science (New York, N. Y.) 2012, 337:1343-1348.
13. Dreyfus C., Ekiert D., Wilson I. Structure of a classical broadly neutralizing stem antibody in complex with a pandemic H2 influenza virus hemagglutinin. J Virol 2013, 87:7149-7154.
14. Okuno Y., Isegawa Y., Sasao F., Ueda S. A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains. J Virol 1993, 67:2552-2558.
15. Wang T., Tan G., Hai R., Pica N., Ngai L., Ekiert D., Wilson I., García-Sastre A., Moran T., Palese P. Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes. Proc Natl Acad Sci U S A 2010, 107:18979-18984.
16. Krause J., Tsibane T., Tumpey T., Huffman C., Basler C., Crowe J. A broadly neutralizing human monoclonal antibody that recognizes a conserved, novel epitope on the globular head of the influenza H1N1 virus hemagglutinin. J Virol 2011, 85:10905-10908.
17. Tan G., Krammer F., Eggink D., Kongchanagul A., Moran T., Palese P. A pan-H1 anti-hemagglutinin monoclonal antibody with potent broad-spectrum efficacy in vivo. J Virol 2012, 86:6179-6188.
18. Ekiert D., Kashyap A., Steel J., Rubrum A., Bhabha G., Khayat R., Lee J., Dillon M., O'Neil R., Faynboym A., et al. Cross-neutralization of influenza A viruses mediated by a single antibody loop. Nature 2012, 489:526-532.
19. Krammer F., Pica N., Hai R., Margine I., Palese P. Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies. J Virol 2013, 87:6542-6550.
20. Rao S., Kong W.-P., Wei C.-J., Van Hoeven N., Gorres J., Nason M., Andersen H., Tumpey T., Nabel G. Comparative efficacy of hemagglutinin, nucleoprotein, and matrix 2 protein gene-based vaccination against H5N1 influenza in mouse and ferret. PloS One 2010, 5.
21. Gao F., Liao H.X., Hahn B.H., Letvin N.L., Korber B.T., Haynes B.F. Centralized HIV-1 envelope immunogens and neutralizing antibodies. Curr HIV Res 2007, 5:572-577.
22. Muthumani K., Lankaraman K.M., Laddy D.J., Sundaram S.G., Chung C.W., Sako E., Wu L., Khan A., Sardesai N., Kim J.J., et al. Immunogenicity of novel consensus-based DNA vaccines against Chikungunya virus. Vaccine 2008, 26:5128-5134.
23. Tompkins S.M., Zhao Z.S., Lo C.Y., Misplon J.A., Liu T., Ye Z., Hogan R.J., Wu Z., Benton K.A., Tumpey T.M., et al. Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. Emerg Infect Dis 2007, 13:426-435.
24. Chen M.W., Cheng T.J., Huang Y., Jan J.T., Ma S.H., Yu A.L., Wong C.H., Ho D.D. A consensus-hemagglutinin-based DNA vaccine that protects mice against divergent H5N1 influenza viruses. Proc Natl Acad Sci U S A 2008, 105:13538-13543.
25. Laddy D.J., Yan J., Corbitt N., Kobasa D., Kobinger G.P., Weiner D.B. Immunogenicity of novel consensus-based DNA vaccines against avian influenza. Vaccine 2007, 25:2984-2989.
26. Weaver E.A., Rubrum A.M., Webby R.J., Barry M.A. Protection against divergent influenza H1N1 virus by a centralized influenza hemagglutinin. PLoS One 2011, 6:e18314.
27. Giles B., Ross T. A computationally optimized broadly reactive antigen (COBRA) based H5N1 VLP vaccine elicits broadly reactive antibodies in mice and ferrets. Vaccine 2011, 29:3043-3054.
28. Giles B., Crevar C., Carter D., Bissel S., Schultz-Cherry S., Wiley C., Ross T. A computationally optimized hemagglutinin virus-like particle vaccine elicits broadly reactive antibodies that protect nonhuman primates from H5N1 infection. J Infect Dis 2012, 205:1562-1570.
29. Giles B., Bissel S., Dealmeida D., Wiley C., Ross T. Antibody breadth and protective efficacy are increased by vaccination with computationally optimized hemagglutinin but not with polyvalent hemagglutinin-based H5N1 virus-like particle vaccines. Clin Vaccine Immunol 2012, 19:128-139.
30. Laddy D.J., Yan J., Kutzler M., Kobasa D., Kobinger G.P., Khan A.S., Greenhouse J., Sardesai N.Y., Draghia-Akli R., Weiner D.B. Heterosubtypic protection against pathogenic human and avian influenza viruses via in vivo electroporation of synthetic consensus DNA antigens. PLoS One 2008, 3:e2517.
31. Xu C., Dong L., Xin L., Lan Y., Chen Y., Yang L., Shu Y. Human avian influenza A (H5N1) virus infection in China. Sci China C Life Sci 2009, 52:407-411.
32. Wilson I., Skehel J., Wiley D. Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 A resolution. Nature 1981, 289:366-373.
33. Caton A., Brownlee G., Yewdell J., Gerhard W. The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype). Cell 1982, 31:417-427.
34. Koel B.F., Burke D.F., Bestebroer T.M., van der Vliet S., Zondag G.C., Vervaet G., Skepner E., Lewis N.S., Spronken M.I., Russell C.A., et al. Substitutions near the receptor binding site determine major antigenic change during influenza virus evolution. Science 2013, 342:976-979.
35. Carter D., Bloom C., Nascimento E., Marques E., Craigo J., Cherry J., Lipman D., Ross T. Sequential seasonal H1N1 influenza virus infections protect ferrets against novel 2009 H1N1 influenza virus. J Virol 2013, 87:1400-1410.
36. Throsby M., Van Den Brink E., Jongeneelen M., Poon L., Alard P., Cornelissen L., Bakker A., Cox F., van Deventer E., Guan Y., et al. Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+memory B cells. PloS One 2008, 3.
37. Wang T., Tan G., Hai R., Pica N., Petersen E., Moran T., Palese P. Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins. PLoS Pathog 2010, 6.
38. Clementi N., De Marco D., Mancini N., Solforosi L., Moreno G., Gubareva L., Mishin V., Di Pietro A., Vicenzi E., Siccardi A., et al. A human monoclonal antibody with neutralizing activity against highly divergent influenza subtypes. PloS One 2011, 6.
39. De Marco D., Clementi N., Mancini N., Solforosi L., Moreno G., Sun X., Tumpey T., Gubareva L., Mishin V., Clementi M., et al. A non-VH1-69 heterosubtypic neutralizing human monoclonal antibody protects mice against H1N1 and H5N1 viruses. PloS One 2012, 7.
40. Kashyap A., Steel J., Rubrum A., Estelles A., Briante R., Ilyushina N., Xu L., Swale R., Faynboym A., Foreman P., et al. Protection from the 2009 H1N1 pandemic influenza by an antibody from combinatorial survivor-based libraries. PLoS Pathog 2010, 6.
41. Ekiert D., Friesen R., Bhabha G., Kwaks T., Jongeneelen M., Yu W., Ophorst C., Cox F., Korse H., Brandenburg B., et al. A highly conserved neutralizing epitope on group 2 influenza A viruses. Science (New York, N.Y.) 2011, 333:843-850.
42. Li G.M., Chiu C., Wrammert J., McCausland M., Andrews S.F., Zheng N.Y., Lee J.H., Huang M., Qu X., Edupuganti S., et al. Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells. Proc Natl Acad Sci U S A 2012, 109:9047-9052.
43. Krammer F., Palese P. Influenza virus hemagglutinin stalk-based antibodies and vaccines. Curr Opin Virol 2013, 3:521-530.
44. Harris A.K., Meyerson J.R., Matsuoka Y., Kuybeda O., Moran A., Bliss D., Das S.R., Yewdell J.W., Sapiro G., Subbarao K., et al. Structure and accessibility of HA trimers on intact 2009 H1N1 pandemic influenza virus to stem region-specific neutralizing antibodies. Proc Natl Acad Sci U S A 2013, 110:4592-4597.
45. Corti D., Suguitan A.L., Pinna D., Silacci C., Fernandez-Rodriguez B.M., Vanzetta F., Santos C., Luke C.J., Torres-Velez F.J., Temperton N.J., et al. Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J Clin Invest 2010, 120:1663-1673.
46. Margine I., Hai R., Albrecht R., Obermoser G., Harrod A., Banchereau J., Palucka K., García-Sastre A., Palese P., Treanor J., et al. H3N2 influenza virus infection induces broadly reactive hemagglutinin stalk antibodies in humans and mice. J Virol 2013, 87:4728-4737.
47. Corti D., Voss J., Gamblin S.J., Codoni G., Macagno A., Jarrossay D., Vachieri S.G., Pinna D., Minola A., Vanzetta F., et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 2011, 333:850-856.
48. Wrammert J., Koutsonanos D., Li G.-M., Edupuganti S., Sui J., Morrissey M., McCausland M., Skountzou I., Hornig M., Lipkin W., et al. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med 2011, 208:181-193.
49. Thomson C.A., Wang Y., Jackson L.M., Olson M., Wang W., Liavonchanka A., Keleta L., Silva V., Diederich S., Jones R.B., et al. Pandemic H1N1 influenza infection and vaccination in humans induces cross-protective antibodies that target the hemagglutinin stem. Front Immunol 2012, 3:87.
50. Krammer F., Pica N., Hai R., Tan G., Palese P. Hemagglutinin stalk-reactive antibodies are boosted following sequential infection with seasonal and pandemic H1N1 influenza virus in mice. J Virol 2012, 86:10302-10307.
51. Pica N., Hai R., Krammer F., Wang T., Maamary J., Eggink D., Tan G., Krause J., Moran T., Stein C., et al. Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses. Proc Natl Acad Sci U S A 2012, 109:2573-2578.
52. Miller M., Tsibane T., Krammer F., Hai R., Rahmat S., Basler C., Palese P. 1976 and 2009 H1N1 influenza virus vaccines boost anti-hemagglutinin stalk antibodies in humans. J Infect Dis 2013, 207:98-105.
53. Nabel G., Fauci A. Induction of unnatural immunity: prospects for a broadly protective universal influenza vaccine. Nat Med 2010, 16:1389-1391.
54. Graves P., Schulman J., Young J., Palese P. Preparation of influenza virus subviral particles lacking the HA1 subunit of hemagglutinin: unmasking of cross-reactive HA2 determinants. Virology 1983, 126:106-116.
55. Bommakanti G., Citron M.P., Hepler R.W., Callahan C., Heidecker G.J., Najar T.A., Lu X., Joyce J.G., Shiver J.W., Casimiro D.R., et al. Design of an HA2-based Escherichia coli expressed influenza immunogen that protects mice from pathogenic challenge. Proc Natl Acad Sci 2010, 107.
56. Steel J., Lowen A., Wang T., Yondola M., Gao Q., Haye K., García-Sastre A., Palese P. Influenza virus vaccine based on the conserved hemagglutinin stalk domain. mBio 2010, 1.
57. Hai R., Krammer F., Tan G., Pica N., Eggink D., Maamary J., Margine I., Albrecht R., Palese P. Influenza viruses expressing chimeric hemagglutinins: globular head and stalk domains derived from different subtypes. J Virol 2012, 86:5774-5781.
58. Margine I., Krammer F., Hai R., Heaton N., Tan G., Andrews S., Runstadler J., Wilson P., Albrecht R., García-Sastre A., et al. Hemagglutinin stalk-based universal vaccine constructs protect against group 2 influenza A viruses. J Virol 2013, 87:10435-10446.
59. Soding J. Protein homology detection by HMM-HMM comparison. Bioinformatics 2005, 21:951-960.